Professor Robert Clarke
- Causes and consequences of frailty in older people in China (MRC PHRU)
- Causes and consequences of heart failure in Chinese adults (MRC PHRU)
- Causes and consequences of frailty in 0.5M adults living in China
- Developing novel genetic risk scores for prediction of cardiovascular disease
- Patterns, determinants and prognosis of multi-morbidity associated with major cardiometabolic diseases in Chinese adults
- Prediction of cardiovascular disease in 0.5M adults living in the UK: evaluation of novel risk factors using modern statistical approaches
MD, FRCP, FFPH, FFPHI, MSc, DCH
Professor of Epidemiology and Public Health Medicine
- Clinical Trial Service Unit and Epidemiological Studies Unit
Robert Clarke is a Professor of Epidemiology and Public Health Medicine at the Clinical Trial Service Unit (CTSU), Nuffield Department of Population Health, University of Oxford and Consultant in Public Health Medicine and Director of the MSc course in Global Health Science. He qualified in clinical medicine in Ireland and worked for 5 years in internal medicine and 4 years in cardiology. After 2 years in clinical pharmacology at Vanderbilt University, Nashville, USA, he joined CTSU in 1991 and specialised in Cardiovascular Epidemiology.
His main research interests are to understand the importance of classical and novel risk factors for occlusive vascular diseases. He led several large observational studies and meta-analyses of observational studies and randomized trials (eg, Whitehall study, PROCARDIS, CARDIoGRAMplusC4D, B-Vitamin Treatment Trialists’ Collaboration and the BEST-D trial). He also worked extensively on the Prospective Studies Collaboration and the China Kadoorie Biobank (CKB) study. He currently leads a research programme to assess the importance of blood pressure, blood lipids, and novel biomarkers (including genetic markers, cytokines, proteomics and metabolomics) for occlusive vascular diseases in the CKB study. His work has been widely cited (200 publications, H-index of 54) and is listed in Tomson Reuters’ Most Influential Scientific Minds 2014.
Blood Pressure and Risk of Subarachnoid Hemorrhage in China.
McGurgan IJ. et al, (2018), Stroke
Metabolomic Consequences of Genetic Inhibition of PCSK9 Compared With Statin Treatment
Sliz E. et al, (2018), Circulation, 138, 2499 - 2512
Diabetes, Plasma Glucose, and Incidence of Fatty Liver, Cirrhosis, and Liver Cancer: A Prospective Study of 0.5 Million People.
Pang Y. et al, (2018), Hepatology, 68, 1308 - 1318
Cardiovascular risk factors and frailty in a cross-sectional study of older people: implications for prevention.
Wong TY. et al, (2018), Age Ageing, 47, 714 - 720
Questioning the Associations of ω-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks-Reply.
Clarke RJ. et al, (2018), JAMA Cardiol, 3, 781 - 782